The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1563
Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza
Download PDF:   US English
 Select a term to see related articles  baloxavir marboxil   FluMist   influenza   Influenza vaccine   Oseltamivir   Peramivir   Rapivab   Relenza   Tamiflu   Xofluza   Zanamivir 

Antiviral drugs can be used for treatment and prophylaxis of seasonal influenza (see Table 1). Frequently updated information on influenza activity, influenza testing, and antiviral resistance is available from the CDC at www.cdc.gov/flu.

ANTIVIRAL DRUGS — The neuraminidase inhibitors oseltamivir (Tamiflu, and generics), which is taken orally, and zanamivir (Relenza), which is inhaled, are FDA-approved for prophylaxis and treatment of acute uncomplicated influenza. The IV neuraminidase inhibitor peramivir (Rapivab) and the oral polymerase acidic (PA) endonuclease inhibitor baloxavir marboxil (Xofluza) are FDA-approved only for treatment of acute uncomplicated influenza.1,2 The neuraminidase inhibitors and baloxavir are active against both influenza A and B viruses.

TREATMENT — The CDC recommends antiviral treatment as soon as possible after illness onset for all people with suspected or confirmed influenza infection who have severe, complicated, or progressive illness, require hospitalization, or are at higher risk for complications, including children <5 years old (children <2 years old are at highest risk), people <19 years old receiving long-term aspirin therapy, adults ≥65 years old, extremely obese people (BMI ≥40), women who are pregnant or ≤2 weeks postpartum, people of American Indian or Alaska Native heritage, residents of nursing homes or other chronic care facilities, and people who are immunosuppressed or have chronic medical conditions (including pulmonary, cardiovascular, renal, hepatic, hematologic, metabolic, neurologic, or neurodevelopmental disorders).3-5

In previously healthy people with suspected or confirmed influenza who are not at high risk for complications, antiviral treatment can be considered if it can be started within 48 hours of illness onset.

For treatment of outpatients with acute uncomplicated influenza, the CDC recommends treatment with oseltamivir, zanamivir, peramivir, or baloxavir. There are no data that suggests superiority of one drug over another in such patients; choice of drug should be based on patient characteristics (e.g., comorbidities, pregnancy), dosing schedule, adverse effects, and cost. Oseltamivir is preferred for treatment of hospitalized patients and outpatients with severe, complicated, or progressive influenza illness (off-label use).3

Because false negative results can occur with some influenza tests, patients with severe or complicated illness and those at higher risk for complications should be treated with an antiviral drug despite a negative test result, especially when influenza is known to be circulating in the community.6

For a more detailed table, click here.

CHEMOPROPHYLAXIS — Antiviral prophylaxis is recommended to help control institutional influenza outbreaks, and can be considered after exposure for people at high risk for complications who have not received the influenza vaccine this season, received it within the previous 2 weeks, or are unlikely to have responded to vaccination, such as those who are immunosuppressed. It is not recommended for healthy people exposed to influenza or if >48 hours have elapsed since exposure.3

EFFECTIVENESS — Treatment – Use of neuraminidase inhibitors for treatment of uncomplicated influenza shortens the duration of symptoms by about one day in adults.7,8 A meta-analysis of randomized trials in children with influenza found that treatment with oseltamivir within 48 hours of symptom onset reduced illness duration by about 18 hours (by 30 hours when trials that enrolled only children with asthma were excluded from the analysis) and reduced the risk of developing otitis media.9 Although most controlled trials of these drugs have not been powered to assess their efficacy in preventing serious influenza complications, experts have generally interpreted the combined results of controlled trials, observational studies, and meta-analyses as showing that early antiviral treatment of influenza in high-risk patients can reduce the risk of complications.10-12

In clinical trials in otherwise healthy outpatients ≥12 years old with uncomplicated influenza, administration of baloxavir within 48 hours of symptom onset shortened the duration of influenza symptoms by about one day compared to placebo; the time to alleviation of symptoms was about the same with baloxavir and oseltamivir.13 Similar results were reported in a trial of patients at higher risk for influenza complications.14

Prophylaxis – Neuraminidase inhibitors have generally been about 70-90% effective when used for prophylaxis against susceptible strains of seasonal influenza A or B viruses.3

TIMING — Treatment – Neuraminidase inhibitors are most effective when started within 48 hours of illness onset, but the results of some observational studies in hospitalized and critically ill patients suggest that treatment started as late as 4-5 days after illness onset can reduce the risk of complications such as pneumonia, respiratory failure, and death.15-17 Baloxavir should also be given within 48 hours of symptom onset; there are no data on the efficacy of baloxavir started >48 hours after symptom onset. In clinical trials, the time to alleviation of symptoms was shorter in patients who started baloxavir within 24 hours of symptom onset than in those who started it later.13

Prophylaxis – When indicated, prophylaxis with oseltamivir or zanamivir should be started within 48 hours after exposure to the influenza virus and continued for 7 days after the last known exposure. Longer durations of prophylaxis are often recommended for institutional and community outbreaks (see Table 1).

PREGNANCY — Pregnant women are at increased risk for severe complications of influenza, including death. Oseltamivir and zanamivir appear to be safe for use during pregnancy.18,19 Prompt treatment, preferably with oseltamivir, is recommended for women with suspected or confirmed influenza who are pregnant or ≤2 weeks postpartum.20-22

Antiviral prophylaxis can be considered for pregnant women who have had close contact with someone likely to have been infected with influenza. Zanamivir may be preferred for prophylaxis because of its limited systemic absorption, but oseltamivir is a reasonable alternative, especially for women at increased risk for respiratory problems.

LACTATION — Oseltamivir, which is poorly excreted in breast milk, is preferred for treatment of women who are breastfeeding.

RESISTANCE — Nearly all (>99%) of the recently circulating influenza virus strains tested by World Health Organization have been susceptible to neuraminidase inhibitors.23 Reduced susceptibility of some influenza strains (particularly influenza A [H1N1]) to oseltamivir or peramivir can emerge sporadically or during or after treatment, especially in immunocompromised patients with prolonged viral shedding.24,25 Resistant isolates have generally remained susceptible to zanamivir, but reduced susceptibility to zanamivir has also been reported.26,27

Baloxavir is active against neuraminidase inhibitor-resistant strains of influenza, including A(H1N1), A(H5N1), A(H3N2), and B viruses. Amino acid substitutions associated with reduced susceptibility to baloxavir have occurred following treatment with a single dose (in 9.7% of patients in one trial).13 Oseltamivir may be active against influenza strains with reduced susceptibility to baloxavir.

ADVERSE EFFECTS — Nausea, vomiting, and headache are the most common adverse effects of oseltamivir; taking the drug with food may minimize GI adverse effects. Diarrhea, nausea, sinusitis, fever, and arthralgia have been reported with zanamivir. Inhalation of zanamivir can cause bronchospasm; the drug should not be used in patients with underlying airway disease. Diarrhea and neutropenia have occurred with peramivir.

Neuropsychiatric events, including self-injury and delirium, have been reported in patients taking neuraminidase inhibitors, but a causal relationship has not been established, and neuropsychiatric dysfunction is a complication of influenza illness itself.28

Baloxavir was well tolerated in clinical trials. It appears to cause less nausea and vomiting than oseltamivir.2

DRUG INTERACTIONS — Use of a neuraminidase inhibitor or baloxavir within 48 hours before or <2 weeks after administration of the intranasal live-attenuated influenza vaccine (FluMist Quadrivalent) could inhibit replication of the vaccine virus, reducing the vaccine's efficacy.

Coadministration of antacids, laxatives, multivitamins, or other products containing polyvalent cations such as calcium, aluminum, iron, magnesium, selenium, or zinc can reduce serum concentrations of baloxavir and should be avoided.

View the Expanded Table: Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza 2018-2019

  1. Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther 2015; 57:17.
  2. Baloxavir marboxil (Xofluza) for treatment of influenza. Med Lett Drugs Ther 2018; 60:193.
  3. CDC. Influenza antiviral medications: summary for clinicians. Available at: www.cdc.gov. Accessed December 20, 2018.
  4. AE Fiore et al. Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
  5. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2018-2019. Pediatrics 2018; 142:e20182367.
  6. CDC. Information for clinicians on influenza virus testing. Available at: www.cdc.gov. Accessed December 20, 2018.
  7. J Dobson et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729.
  8. IDSA. Infectious Disease Society of America (IDSA) statement on neuraminidase inhibitors. Available at: www.idsociety.org. Accessed December 20, 2018.
  9. RE Malosh et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis 2018; 66:1492.
  10. In brief: concerns about oseltamivir (Tamiflu). Med Lett Drugs Ther 2015; 57:14.
  11. MK Doll et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother 2017; 72:2990.
  12. J Katzen et al. Early oseltamivir after hospital admission is associated with shortened hospitalization: a five-year analysis of oseltamivir timing and clinical outcomes. Clin Infect Dis 2018 October 9 (epub).
  13. FG Hayden et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379:913.
  14. MG Ison et al. Phase 3 trial of baloxavir marboxil in high risk influenza patients (CAPSTONE-2 Study). Presented at ID Week, San Francisco, CA, Oct 3-7, 2018. Abstract LB16. Available at: https://academic.oup.com. Accessed December 20, 2018.
  15. JK Louie et al. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics 2013; 132:e1539.
  16. SG Muthuri et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395.
  17. JK Louie et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198.
  18. S Graner et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ 2017; 356:j629.
  19. V Ehrenstein et al. Oseltamivir in pregnancy and birth outcomes. BMC Infect Dis 2018; 18:519.
  20. ACOG Committee Opinion No. 753: assessment and treatment of pregnant women with suspected or confirmed influenza. Obstet Gynecol 2018; 132:e169.
  21. IK Oboho et al. Benefit of early initiation of influenza antiviral treatment to pregnant women hospitalized with laboratory-confirmed influenza. J Infect Dis 2016; 214:507.
  22. CDC. Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. Available at: www.cdc.gov/flu. Accessed December 20, 2018.
  23. A Lackenby et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antiviral Res 2018; 157:38.
  24. AC Hurt et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148.
  25. C Renaud et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011; 17:653.
  26. E Takashita et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Euro Surveill 2016; 21:pii=30258.
  27. R Trebbien et al. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Euro Surveill 2017; 22:pii=30445.
  28. S Toovey et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther 2012; 29:826.
© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.